Concepedia

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Lourdes Anta, Josep M. Llibre, Eva Poveda, José L Blanco, Marta Álvarez, Maria Jesús Pérez‐Elías, Antonio Aguilera, Estrella Caballero, Carmen de Mendoza

AIDS · 2012 · 59 citations · 13 references

DOIFull text

Open access

Abstract

RPV resistance is overall recognized in nearly 20% of patients failing other NNRTIs. It is more common following ETR (27.6%) or NVP (25%) failures than EFV (14.5%). E138 mutants are rarely seen in this context.

References

13

UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1

&NA; · Infectious Diseases in Clinical Practice · 2001 · 1.7K citations

, , +16

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2011 · 399 citations

, , +8

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet et al. · The Lancet · 2011 · 369 citations

, , +9

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Hilde Azijn, Ilse Tirry, Johan Vingerhoets et al. · Antimicrobial Agents and Chemotherapy · 2009 · 291 citations · Full text

, , +15

19th Conference on Retroviruses and Opportunistic Infections

晃史 髙折 · HIV感染症とAIDSの治療 · 2012 · 196 citations

, , +2